Coalition of Pet Drug Manufacturers Inc
Nonprofit profile at a glance
- EIN
- 874397344
- IRS 990-EZ coverage
- 2022–2024
- Forms available
- Form 990-EZ 2024, Form 990-N 2021
- Location
- Fredericksburg, TX, USA
- Phone
- 8303706554
- Rating confidence
- Limited
- Sector
- Business and Industry
Reported finances
- Revenue
- $47,500
- Expenses
- $45,569
- Assets
- $66,012
- Liabilities
- $0
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
8 people listed
Executive titles in this filing
- CHARLES METZGER (EXECUTIVE DIRECTOR)
People named in this filing
- SUSAN K BUNNING (DIRECTOR)
- CHRISTOPHER C IGNACE (SECRETARY)
- CHARLES METZGER (EXECUTIVE DIRECTOR)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
The coalition of pet drug manufacturers (cpdm) is a venue for the positron emission tomography (pet) drug manufacturing community to advance scientific and regulatory principles associated with the manufacturing of pet drugs. The key purposes of this mission are to: provide a multi-stakeholder forum to address current topics with government agencies and other groups; establish scientifically sound and rational practices for pet drug manufacturing; provide education and training; enable the expansion of new pet drugs into routine manufacturing networks; provide high-value resources to assist pet drug manufacturers with gmp compliance and inspection challenges; align the interests of the community of pet drug manufacturers; and to engage in any and all lawful activities to accomplish the foregoing primary purpose and objectives, except as restricted herein.
What it reported doing in 2024
Over the past year, the coalition has advanced its mission through a wide range of impactful initiatives. We strengthened member interaction by creating a dedicated whatsapp group and held our first board member election, while also appointing michael nazerias as our representative to the iaea technical working group for radiopharmaceutical medicines regulations. Key infrastructure developments included creating an fda 483 and ir database, producing a comprehensive 35 year strategic plan, and establishing three new working groupsmembership education and training, membership engagement, and new member recruitmentto drive the plan's objectives. Our scholarly and regulatory contributions were significant, with the proceedings from the 2023 fda workshop now in press at jnm, the publication of a position paper on stability studies, a jnm letter to the editor on fda reconsiderations around dosimetry rules for first-in-human pet drug studies, and a spotlight article featuring krishna ghosh. We also collaborated on drafting a mita letter to the fda regarding precursor testing. At the snmmi conference, the coalition partnered with rpsc to organize a ce session, delivered presentations and posters on adverse events and sterility assuranceincluding a poster award candidateand hosted a kiosk in the exhibit hall to engage attendees and share resources.
Operating model
- Revenue model
- Membership-supported. 100% of the money available for current operations came from membership dues.
- Distribution model
- Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.
The verdict
- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.
Rating breakdown
- Financial Efficiency: NotEnoughData
- Transparency & Controls: 82
- Sustainability: 56
- Growth: 60
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: Limited
- Program expense ratio: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 52nd percentile among comparable filings
- Major donor itemization: Limited
Sustainability
- Operating margin: 4.1%; rating input score 53; 53rd percentile among comparable filings
- Total-asset coverage ratio: 1.45; rating input score 57; 57th percentile among comparable filings
- Liabilities to assets ratio: 0; rating input score 68; 68th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: 5.9% per year; rating input score 100; 73rd percentile among comparable filings
- Asset growth: 26.2% per year; rating input score 100; 90th percentile among comparable filings
Details
- Where the money goes: Financial trends and filed revenue, expense, asset, and liability detail
- Governance: Filed governance answers
- Accomplishments: 1 filed program accomplishment
- Leadership: top reported pay $0 · 8 people listed
- Consistency: 7 of 7 current checks pass
- Schedules: 1 filed schedules
- Filing history: 3 filing years from 2022 to 2024
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- Review — Sustainability: Operating margin scored 53/100.
- Review — Sustainability: Total-asset coverage ratio scored 57/100.
- Review — Sustainability: Officer compensation ratio scored 56/100.